Sapience is a New York-based biotechnology firm that develops and commercializes peptide therapeutics for the treatment of cancer and infectious diseases... Read more
Sapience is a New York-based biotechnology firm that develops and commercializes peptide therapeutics for the treatment of cancer and infectious diseases... Read more
News
May 21, 2026
PR Newswire
Press Release: Sapience Therapeutics : Sapience Therapeutics Provides Positive Data Update from Phase 2 Trial of Lucicebtide Plus SOC in Patients with Glioblastoma at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
Apr 20, 2026
PR Newswire
Press Release: Sapience Therapeutics : Sapience Therapeutics Presents First Clinical Results from Phase 2 Study of ST316, First-in-Class -catenin Antagonist, in Second-Line Colorectal Cancer at the American Association for Cancer Research (AACR) Annual Meeting 2026
Apr 13, 2026
PR Newswire
Press Release: Sapience Therapeutics : Sapience Therapeutics Announces Participation in the 25th Annual Needham Virtual Healthcare Conference
Mar 18, 2026
PR Newswire
Press Release: Sapience Therapeutics : Sapience Therapeutics to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2026
Jun 02, 2025
StreetInsider
Press Release: Sapience Therapeutics : Sapience Therapeutics Provides Data Update from Phase 2 Trial of Lucicebtide in Patients with Glioblastoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
May 27, 2025
PR Newswire
Press Release: Sapience Therapeutics : Sapience Therapeutics Announces Participation in the Jefferies Global Healthcare Conference
Dec 30, 2024
Pharamceutical Technology
Sapience Therapeutics: Lucicebtide by Sapience Therapeutics for Signet Ring Cell Squamous Cell Carcinoma: Likelihood of Approval
Nov 09, 2024
StreetInsider
Press Release: Sapience Therapeutics : Sapience Therapeutics Presents Clinical Data on Two Lead Programs, Including ST101 Oral Presentation, at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting
Oct 03, 2024
Pharmabiz
Sapience Therapeutics: Sapience Therapeutics begins patient enrolment in phase 2 study of firstinclass catenin antagonist, ST316 in colorectal cancer
Oct 03, 2024
PR Newswire
Press Release: Sapience Therapeutics : Sapience Therapeutics Announces Participation at the 4th Annual Needham Private Biotech Company Virtual 1x1 Forum
